Mologen AG of Germany is expediting discussions with potential pharmaceutical company partners with a view towards starting a Phase 3 study of its lead product for colorectal cancer next year. The product, MGN1703, is a toll-like receptor 9 agonist. ---Subscribe to MedNous to access this article--- Clinical Research Company News
